Perrigo acquires generic Retin-A portfolio

DUBLIN — Perrigo announced Thursday be acquiring Matawan Pharmaceuticals’ portfolio of generic Retin-A products, which are indicated to treat acne vulgaris. Until 2013, Perrigo had been the distributor of authorized generics of Retin-A products. 

 

“We are excited to reacquire this high-barrier to entry product into our unique Rx portfolio,” Perrigo chairman and CEO Joseph Papa said. “This serves as yet another example of our ability to execute on our 'Base Plus Plus Plus' strategy and we believe this margin-enhancing asset superbly complements our already robust Rx portfolio. We remain committed to continue delivering superior value for our shareholders.”

 

The transaction, whose terms haven’t been disclosed, is expected to close in the first quarter of 2016 and is expected to immediately exceed Perrigo’s ROIC threshold. Retin-A's branded and generics sales were $257 million for the 12 months ended October 2015, the company said.